Loading clinical trials...
Loading clinical trials...
A Multicenter, Open, Single Arm Dose-escalation and Dose-expansion Study: to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of FCN-437c Alone or in Combination With Letrozole in ER+/ HER2- Advanced Breast Cancer
Conditions
Interventions
FCN-437c
Letrozole 2.5mg
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, China
Start Date
February 14, 2019
Primary Completion Date
December 31, 2021
Completion Date
June 30, 2022
Last Updated
July 27, 2020
NCT07191730
NCT06797635
NCT06312176
NCT07003841
NCT07396766
NCT06443645
Lead Sponsor
Ahon Pharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions